Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis
- 1 November 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 77 (18) , 1684-1690
Abstract
Objective: In multiple sclerosis (MS), the aim of therapies is to prevent the accumulation of irreversible disability. This is difficult to assess given the short time course of clinical trials. MRI markers and relapses are often used as surrogate of disability in MS studies, but their validity remains controversial. We sought to validate, at the individual patient level, MRI lesions and relapses as surrogates for disability progression over the course of MS trials. Methods: Individual patient data from a large, placebo-controlled trial of interferon β-1a in relapsing-remitting MS (RRMS) were analyzed. The Prentice criteria were applied to evaluate surrogacy of 1-year MRI active lesions and relapses for disability worsening (Expanded Disability Status Scale [EDSS]) over the 2-year follow-up. Results: All Prentice criteria were satisfied. Treatment reduced by 31% the odds of having EDSS worsening over 2 years, reducing the mean number of MRI lesions by 61% and the mean number of relapses by 36% over 1 year. Both 1-year MRI lesion activity and relapses, when considered independently, accounted for more than 60% of the treatment effect on 2-year EDSS worsening. A combination of 1-year MRI lesion activity and relapses explained 100% of the treatment effect on EDSS worsening over 2 years. Conclusions: A combined measure of 1-year changes in MRI lesions and relapses after interferon therapy fully estimated the corresponding effect on 2-year EDSS worsening. This short-term combined measure appears to be a surrogate for disability progression over a longer term when evaluating the effect of interferon in RRMS.Keywords
This publication has 27 references indexed in Scilit:
- Surrogate endpoints for EDSS worsening in multiple sclerosisNeurology, 2010
- The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disabilityBrain, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- MRI ASANOUTCOMEIN MULTIPLE SCLEROSIS CLINICAL TRIALSNeurology, 2009
- Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approachAnnals of Neurology, 2009
- MRI as an outcome in multiple sclerosis clinical trialsNeurology, 2009
- Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapsesMultiple Sclerosis Journal, 2008
- Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment?Annals of Neurology, 2006
- Rating neurologic impairment in multiple sclerosisNeurology, 1983